ICG is a pharma marketing agency — and a pharmaceutical marketing agency, pharma digital marketing partner, pharma advertising agency, and HCP engagement consultancy — built around therapy-aware brand campaigns, CLM content, e-detailing, MR enablement, and Pharos for omnichannel HCP outreach. Built by IIT BHU pharmaceutical engineers who understand what an HCP needs to hear — and what a regulator will object to.
For Indian pharma companies (mid-cap to large), medical-device brands, and biotech — across oncology, cardiology, diabetes, neurology, rare disease, and devices.
Your brand has strong evidence. The field force doesn't know how to communicate it.
This is the most common gap ICG encounters in pharma brand engagements. The data exists. The clinical story is compelling. But somewhere between the medical affairs team and the 3,000 MRs carrying the visual aid, the message becomes generic. "Safe and effective." "Well-tolerated." "First-line option." Phrases that could apply to any drug in the category.
The problem is not the field force. It is the brand communication architecture — built by marketing generalists who understand communication but not the therapeutic nuance that makes the clinical story compelling. ICG is built by pharmaceutical engineers. The nuance is where we start — not where we end up.
Brand strategy grounded in therapeutic area evidence. Promotional campaign development compliant with OPPI, Drug & Magic Remedies Act, and applicable guidelines. Claims mapped to citations before any creative brief is written.
Closed Loop Marketing content for iPad-based HCP detailing. e-Detailing modules for remote engagement. Built for how HCPs actually engage during a 3-minute visit — not for what fits in a slide deck.
Detailing aids, product monographs, comparison charts, objection-handling tools. Every claim referenced. Every comparison compliant. Designed to survive medical review and legal review without a single claim being pulled.
Google Ads for pharma brands — keyword strategy, landing page development, compliance-safe creative. LinkedIn for HCP targeting. Content marketing and SEO for therapy area authority building. Digital marketing that respects the regulatory environment it operates in.
Advisory board facilitation. Speaker bureau development. KOL identification and relationship strategy. Symposia content development. HCP engagement that connects brand investment to measurable prescription intelligence — via Pharos RxFlow.
RxFlow for HCP prescription intelligence. RouteIQ for MR route optimization. Signal for AI MR coaching. Gate for pipeline intelligence. Pulse for the commercial command centre. Explore the Pharos platform →
When a pharma brand manager briefs a generalist marketing agency, the first three meetings are education sessions — explaining the mechanism of action, the clinical evidence, the regulatory environment, the HCP audience's level of scepticism.
When the same brand manager briefs ICG, the first meeting is strategy. The mechanism is understood. The evidence has been read. The regulatory boundaries are known. And the brief focuses immediately on what the brand needs to communicate and to whom.
This is not a small difference. It is the difference between an agency partner and a science partner who also does marketing. The credential is IIT BHU pharmaceutical engineering. The outcome is marketing that doesn't need to be corrected by medical review.
ICG's Co-Founding Team and pharma practice lead are pharmaceutical engineers from IIT BHU's Department of Pharmaceutical Engineering and Technology — B.Tech and M.Tech graduates who have studied drug metabolism, formulation science, pharmacokinetics, and clinical pharmacology.
This is not a credential for a website. It is the reason why ICG manuscripts have fewer scientific errors in medical review, why ICG PSURs have fewer clarification cycles, and why the scoping call for a literature monitoring engagement sounds different from every other agency you've briefed. The science is understood before the brief is written.
ICG's commercial and field force engagements run on RxFlow, RouteIQ, Gate, Signal, and Pulse — five tools that connect field activity to prescription outcomes.
Explore the full Pharos platform →AI Scientific Writing
AI-guided manuscript development from topic selection to submission-ready output. Journal fit intelligence. CONSORT/PRISMA embedded from Day 1.
Literature Monitoring
Adverse-event-driven literature surveillance. Validated PubMed queries. De-duplication. Evidence scoring. Audit-ready search logs.
PV Resource Allocation
Risk-based drug tiering and defensible PV staffing. Objective tier from signal frequency and seriousness. Headcount you can defend with data.
Drug AE Intelligence
Single-drug adverse event visualization dashboard. On-demand data refresh. Spot signals before they escalate.
Prescription Intelligence
HCP-level prescription intelligence. Visit history, AI call analysis. See Rx switching risk before it moves.
Explore RxFlow →MR Route Optimization
AI route planning for medical representatives. Priority-scored daily call plans. Right HCP, right day, every day.
Explore RouteIQ →Sales Pipeline Intelligence
Stagnation alerts before deals go cold. Stage bottleneck heatmaps. Intervene before it's too late.
Explore Gate →MR AI Coaching
AI coaching after every HCP visit. Post-visit feedback, objection analysis. Turn each visit into a prescription.
Explore Signal →Pharma MIS Command Centre
360° commercial intelligence for leadership. Revenue, field force, distributor, market — one real-time view.
Explore Pulse →Every ICG pharma engagement runs on some combination of these nine modules. The pilot engagement determines which ones are active from Day 1.
Start a pilot project →Every ICG pharma engagement is led personally by Aditi Tripathi — M.Pharm, IIT BHU — with Abhash, Deep and Rohit (Co-Founding Team) bringing the scientific rigour, delivery architecture and commercial lens built across 8+ years. IIT BHU pharmaceutical engineers at every level of the engagement.
60+ specialists. One process. Every deliverable in-house. Gurgaon, since 2018.
Strategy Lead · IIT BHU + IIM Bangalore
Leads scientific strategy and quality governance. Sets the standard for scientific rigour across every engagement.
Profile →
Operations Lead · IIT BHU (B.Tech + M.Tech)
Owns the AI-powered delivery system — the multi-tenant operations layer that runs every pharma engagement on time and on spec.
Profile →
Business & Growth Lead · IIT BHU + IIM Rohtak
Pharma engineer who owns business growth and the commercial lens connecting science to prescription outcomes.
Profile →
IIT BHU · M.Pharm
Aditi leads every pharma engagement end to end — from scoping the scientific writing architecture to governing quality across delivery. Her M.Pharm from IIT BHU means she doesn't need the science explained to her. "She explains it to everyone else."
Pilot engagement: one marketing deliverable, full ICG process — claims mapped to citations, compliance-cleared, field-force-ready. No commitment to start.
The phrase "pharma marketing agency" covers a wide range of service models — from full-service HCP engagement agencies with medical writers, regulatory affairs consultants, and field force trainers, to boutique agencies that produce branded promotional materials and call it pharma marketing. The distinction matters when evaluating who can actually help.
The six functional areas that a pharma marketing engagement with ICG covers:
HCP engagement: The strategy and execution layer for how the pharmaceutical company communicates with healthcare professionals across all channels — field force (MR) detailing, digital HCP platforms (Curofy, Docplexus), KOL advisory programmes, and CME sponsorship within UCPMP 2024 guidelines. ICG's HCP engagement work is anchored in clinical evidence — every engagement touchpoint is built around a defensible clinical message, not a promotional claim. Medical communications (MedComm): The creation of HCP-facing clinical content — therapy area literature, product monographs, medical information letters, scientific advisory board documentation, and publications strategy. ICG's MedComm team includes IIT BHU pharmacy engineers and medical writers with pharmaceutical sciences training — not general content writers applying a healthcare template. Brand marketing: Patient-facing and trade-facing brand campaigns within UCPMP and Schedule H regulatory constraints. Campaigns that build therapy area awareness among patients (for self-directed conditions like type 2 diabetes, hair loss, or OTC-adjacent categories) and trade campaigns that support pharmacist and stockist engagement within compliance boundaries. Pharmacovigilance (PV) support: Documentation support for adverse event tracking, periodic safety update reports (PSUR), and regulatory submission collateral. ICG supports PV activities as part of broader pharma marketing engagements for clients who need an integrated documentation capability rather than a standalone PV contractor. Scientific writing: Clinical study reports, investigator brochures, regulatory dossier components, and congress abstract preparation. ICG's scientific writing follows ICH GCP guidelines and is structured for the submission requirements of CDSCO (Central Drugs Standard Control Organisation) and, where applicable, international regulatory bodies. Media and stakeholder communication: Press releases, investor communications (for publicly listed pharma companies), and media engagement for therapy area awareness campaigns. All media communication is reviewed for Schedule J (Drugs and Cosmetics Act) compliance — conditions and drugs where public advertising is restricted.Most pharma company RFP processes ask the same questions: show us a case study, tell us your team credentials, what is your pricing? These questions produce polished pitch decks, not reliable vendor intelligence.
Eight questions that surface what a pharma marketing agency actually is:
1. Who reviews your content for regulatory compliance, and can you show me a redlined example? Any serious pharma marketing agency has a documented sequential review process — Medical, Legal, Regulatory. Ask to see a real redlined document showing each reviewer's comments and the resolution. Agencies without this process are producing content that has not been independently compliance-reviewed. 2. What is your team's scientific background for the therapy area I need? For cardiology content, ask whether the medical writer has a pharmacy or life sciences degree with cardiovascular pharmacology background. For oncology, ask about oncology-specific training. Generic content writers with a "healthcare vertical" do not have the scientific depth required for credible HCP-facing content. 3. How do you handle UCPMP 2024 changes in ongoing content — not just at launch? The UCPMP 2024 revision is recent. Any agency that was producing UCPMP 2015-era content needs to demonstrate that their existing content library has been audited and updated. Ask specifically what they changed in response to the 2024 revision. 4. What is your process for prescription outcome measurement? Measuring whether marketing activity changes prescriber behaviour requires prescription data linkage — IQVIA Rx data, panel-based surveys, or representative prescriber tracking. Agencies that only measure reach and engagement without connecting to prescription leading indicators are measuring activity, not impact. 5. Can you describe a compliance issue that arose in a past engagement and how it was handled? Agencies with real pharma marketing experience have encountered compliance issues. An agency that claims no compliance issues have ever arisen either has very limited experience or is not disclosing accurately. 6. What audit documentation do you produce and retain? UCPMP 2024 requires 5-year retention of promotional material audit trails. Ask the agency how they produce and retain this documentation — not just whether they do. 7. How do you manage content versioning for digital HCP channels? Digital content is updated at a much faster cadence than print. Weekly or monthly digital detail updates require a content workflow that can move brief-to-review-to-distribution in 5–10 days without bypassing compliance review. Ask the agency to walk through their digital content versioning workflow. 8. What is your minimum engagement commitment and what does the first 30 days produce? Agencies that require 6-month minimum commitments before producing any deliverable are building in revenue security at the client's expense. ICG's pharma engagements begin with a documented deliverable in the first 30 days — a content audit, a UCPMP compliance review of existing materials, or the first MedComm piece — so the client has a quality signal before committing to longer-term scope.| Engagement type | Monthly range | What is included |
|---|---|---|
| Retainer — single therapy area | ₹3–8L/month | HCP content, field force support, 1–2 MedComm pieces/month, digital HCP |
| Retainer — multi-therapy area | ₹8–20L/month | Dedicated therapy area teams, full MedComm pipeline, KOL programme support |
| Project — medical communications | ₹50,000–₹3L/project | Per monograph, advisory board deck, publication abstract, or field force aid |
| Enterprise — full-service | ₹15L+/month | HCP engagement, MedComm, brand, PV support, media, analytics |
Note: These ranges reflect ICG's engagement structure and market benchmarking. Individual agencies vary significantly in pricing and scope definition. Always request a scope-of-work document before accepting a price quote.
Both. ICG's pharma marketing engagements include MNC pharma (India affiliate marketing and medical communications), large domestic Indian pharma groups (full-service HCP engagement), and specialty pharma companies (focussed therapy area campaigns). The regulatory framework and scientific standards are the same regardless of company type — ICG does not produce content at different quality levels for domestic vs MNC clients.
ICG's pharma marketing team includes IIT BHU pharmaceutical engineering graduates, trained medical writers with life sciences backgrounds, and regulatory affairs consultants with CDSCO submission experience. General digital agencies applying healthcare templates do not have this scientific foundation. For HCP-facing content, the scientific credential of the writer matters — a cardiologist reviewing a competitor's MR detail versus ICG's detail will notice the difference in clinical depth.
Retainer engagements run on 6–12 month initial commitments with quarterly reviews. Project engagements (per-deliverable MedComm) are scoped individually. ICG's practice: the first 60 days of any new pharma engagement include a UCPMP compliance audit of the client's existing promotional materials — identifying and correcting compliance risks before producing new content.
Yes, through IQVIA prescription data partnerships and prescriber tracking panel programmes. ICG designs pharma marketing campaigns with measurement architecture built in from the start — not bolted on as a retrospective reporting exercise. Prescription leading indicators (new patient starts, share of voice by prescriber segment) are defined as KPIs at engagement initiation.
ICG's pharma marketing experience spans: cardiology (statins, antihypertensives, antiplatelets), oncology (targeted therapy, immunotherapy, supportive care), CNS (antidepressants, antiepileptics, neurodegenerative disease), women's health (oral contraceptives, HRT, fertility), metabolic disease (diabetes, obesity, lipid management), and respiratory (COPD, asthma). For novel therapy areas not listed, ICG conducts a therapy area immersion before accepting an engagement — to ensure the team has the scientific foundation required.
Field force training is part of ICG's pharma marketing offering. ICG's HSE-1 programme (Medical Representative to Territory Manager) is the training delivery mechanism — covering clinical evidence fluency, the 90-second detailing framework, UCPMP 2024 compliance, and territory business planning. For pharma clients, the training is customised to the specific therapy area and product portfolio. Read: Medical representative training 2026 →
Pharos is ICG's pharma marketing intelligence platform — managing the HCP engagement intelligence, content workflow, and competitive monitoring for pharma clients. Pharos tracks competitive share of voice in HCP digital channels, manages the sequential content review workflow from brief to distribution, and provides the audit documentation trail required by UCPMP 2024. Pharos access is included in ICG's pharma marketing retainers at the Full and Enterprise tiers.
Contact ICG pharma marketing team → · Read: Pharma marketing pillar guide India → · Read: Medical representative training 2026 →Our team member will reach out within one business day. In the meantime — WhatsApp Rohit directly for the fastest reply.
💬 Message Rohit on WhatsApp
For pharma / life sciences — medical writing, scientific communications, regulatory support — I reply personally.
Message Rohit on WhatsAppOr call: +91 81302 26224